Mr. Will is an operating executive with extensive experience founding, funding, operating, and selling medical device companies. Prior to EBR Systems, he led the negotiation of Ardian’s acquisition by Medtronic for over $800 million. Will was also founding Managing Director at Split Rock Partners and a Partner at St. Paul Venture Capital. Previously, he was Founder, Chairman & CEO of The Foundry, co-founding 11 companies there including Ardian, Evalve (acquired by Abbott Laboratories for $450 million), and Concentric Medical (acquired by Stryker for $135 million). Earlier in his career, Will served as CEO of AneuRx, acquired by Medtronic, growing to over $150 million the year of launch. Prior to that, he was President & CEO of Devices for Vascular Intervention, growing the business to 550 employees, $100 million revenue run rate, and acquisition by Eli Lilly. Will holds more than 30 issued patents and earned his Master of Science in Management from MIT and Bachelor of Science in Zoology from the University of Maryland.

Mr. McCutcheon has over 40 years of sales, marketing, and general management experience in medical devices. McCutcheon started his career at American Hospital Supply (acquired by Baxter International) and has spent the past 20 years at start-ups, including DVI (acquired by Eli Lily), Perclose (acquired by Abbott Laboratories), Emphasys Medical (acquired by Pulmonx), Ventus Medical, and Ceterix Orthopaedics (acquired by Smith & Nephew). He has served on numerous Boards including Emphasys Medical, Ventus Medical, Disc Dynamics, Zeltiq (ZLTQ), Advanced Stent Technologies (acquired by Boston Scientific), and LuMend (acquired by Johnson & Johnson). McCutcheon holds Bachelor of Arts degrees in Economics and Psychology from the University of California, Los Angeles, and a Master of Business Administration from the UCLA Anderson Graduate School of Management.

Mr. Doherty was appointed as Chief Financial Officer in September 2023 and brings over 30-years of experience across technology, healthcare and finance to the role. Mr. Doherty has a proven track record of developing high performing finance functions and medical device companies including his previous role as CFO of Acutus Medical (NASDAQ:AFIB), a medical technology company specializing in cardiac arrhythmia and atrial fibrillation treatment. Prior to this, he held key positions at Volcano Corporation (acquired by Philips) for 12 years. Doherty holds a Bachelor of Science degree in Business Administration and Finance, from the San Diego State University.

‍

Ms. Bhat has over 25 years of experience in public affairs, public policy, clinical, quality, and regulatory roles in medical devices. She led several successful pivotal clinical trials and multiple registries and secured regulatory approvals and clearances in the US and internationally for Class II and III cardiovascular systems. Most recently, Bhat served as Consulting Vice-President RA/Clinical for companies in the reproductive, GI, neurological, urological, and cardiovascular domains such as Kyma Medical (acquired by Zoll) as the Founder/Principal of her own consulting company. Prior to that, Bhat was the VP of RA/QC at Barrx Medical (acquired by Covidien, then Medtronic), VP of RA/Clinical at Corventis (acquired by Medtronic), and she held management positions at Guidant and Abbott Vascular. Bhat is a book author on child advocacy and serves as visiting faculty at San Jose State University. She holds a Bachelor of Science in Biology from the University of Mumbai, a diploma in Mass Communications from Sophia Polytech, and a Master of Public Policy from Duke University.

Mr. Hendricksen has over 25 years of medical device product development and manufacturing experience. Prior to joining EBR Systems, Hendricksen served as Chief Operating Officer at Ceterix Orthopaedics where he led the development of the NOVOSTITCH Pro Meniscal Repair System. Ceterix was acquired in 2019 by Smith+Nephew at which time Hendricksen assumed the role of Site Leader, where he scaled and integrated operations not only for Ceterix but also for Tusker Medical, another Smith+Nephew acquisition. Before Ceterix, Hendricksen was Vice President of R&D at Foundry NewcoXI and served in engineering roles of increasing responsibility at Emphasys Medical, Cardica, and IDEO Product Development. Hendricksen is an inventor on over 80 issued patents, and he holds a Master of Science in Mechanical Engineering from Stanford University and a Bachelor of Science in Mechanical Engineering from Northwestern University.

Dr. Kubo joined EBR in January 2019 and holds the same position at Heart Leaflet Technologies, where he oversees clinical trials for a next-generation Transcatheter Aortic Valve Replacement (TAVR). Kubo's career also includes roles as Executive Director of Merck's Academic and Professional Affairs department, Professor of Medicine, Co-Director of Clinical Cardiology, and Medical Director of the Heart Failure-Heart Transplantation Program at the University of Minnesota. Renowned for his research in heart failure, he has published over 250 papers and abstracts. Kubo earned his undergraduate degree in biology from Dartmouth College and his MD from Cornell University Medical College. He is a Fellow of both the American College of Cardiology and the American Heart Association.

Mr. Shute has over 25 years of medical device experience and has led the successful commercialization of new technologies and products working in the corporate, start-up, and distributor settings. He brings a strong business, clinical training, and sales management background to the team, including positions at St. Jude Medical, Endocardial Solutions, and Getz Brothers. Shute received his Bachelor of Science from the University of Wollongong, Australia. Shute previously held the position of Chairman of the Cardiac Rhythm Management section of the Association of British Healthtech Industries Ltd (ABHI).

Mr. Strandberg, with a B.S. in Finance from Florida State University and over two decades in the medical device sales industry, has demonstrated exceptional leadership in strategic planning and operational oversight. At AtriCure, as Senior Vice President of the Hybrid Therapies Division, he led sales and marketing efforts, leveraging relationships across the medical field to drive growth and market expansion. His career includes pivotal roles at Boston Scientific, St. Jude Medical, and Guidant Corporation, where he launched various cardiac therapies and led teams to substantial achievements. Strandberg's educational advancements through executive programs at the University of Texas and the Wharton School, coupled with his certification in healthcare finance and specialized cardiac device knowledge, underscore his strategic leadership and contributions to the industry.

Dr. Willis is an electrical engineer with extensive experience in signal processing applications and has worked in medical devices for over 20 years, all in technical leadership capacities for development of novel technologies for cardiac electrophysiology. He previously held senior positions at Boston Scientific and Cardiac Pathways. Willis is an inventor on more than 28 issued patents. He earned his Bachelor of Science in Electrical Engineering from the University of California, San Diego, and his Master of Science and Ph.D. from the University of Illinois Urbana-Champaign.